Ticker Hub
ZVRA — AI Analysis & Sentiment
7 recent AI-generated analyses for ZVRA. Sentiment and confidence insights updated continuously.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Zevra's strong Q1 2026 financial performance, marked by significant revenue growth, a swing to net income, and a debt-free balance sheet, establish...
May 6, 2026Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Zevra's strategic divestiture, debt elimination, and litigation settlement significantly strengthen its financial position and clarify its focus on...
Mar 16, 2026Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra's Q4 and FY2025 results show substantial revenue growth and a significant shift to net income, largely driven by a one-time gain. The strong ...
Mar 9, 2026Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra Therapeutics' strong Q4 and FY2025 financial performance, marked by a significant swing to profitability and robust revenue growth, suggests ...
Mar 9, 2026Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra Therapeutics achieved a significant financial turnaround in 2025, reporting strong revenue growth and a swing to net income. This positive sh...
Mar 9, 2026Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra Therapeutics reported significant top-line growth and a strong cash balance, primarily driven by its MIPLYFFA product. While headline profita...
Mar 9, 2026Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Zevra Therapeutics has achieved a significant financial turnaround, transitioning from a substantial net loss to strong profitability in 2025. This...
Mar 9, 2026